HEMOSTEMIX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.045 CAD | +12.50% |
|
+12.50% | -35.71% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 6.1M 8.32M |
|---|---|---|---|---|---|
| Net income 2022 | -5M -6.82M | Net income 2023 | -2M -2.73M | EV / Sales 2022 | - |
| Net Debt 2022 | 3.99M 5.44M | Net Debt 2023 | 4.17M 5.68M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-2.41
x | P/E ratio 2023 |
-2.31
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hemostemix Inc.
More press releases
More news
| 1 day | +12.50% | ||
| 1 week | +12.50% | ||
| Current month | +12.50% | ||
| 1 month | -10.00% | ||
| 3 months | -43.75% | ||
| 6 months | -40.00% | ||
| Current year | -35.71% |
1 week
0.04
0.05
1 month
0.040.05
Current year
0.040.11
1 year
0.040.18
3 years
0.040.42
5 years
0.001.00
10 years
0.0025.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Smeenk
FOU | Founder | - | 05-12-31 |
Christina Wu
DFI | Director of Finance/CFO | - | 20-03-04 |
Peter Pavlin
COO | Chief Operating Officer | - | 22-05-18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Peter Lacey
CHM | Chairman | 67 | 20-03-10 |
Ronnie Hershmann
BRD | Director/Board Member | - | 20-02-08 |
Thomas Smeenk
FOU | Founder | - | 05-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 0.045 | +12.50% | 11,000 |
| 24-05-17 | 0.04 | 0.00% | 23,000 |
| 24-05-15 | 0.04 | 0.00% | 157,250 |
| 24-05-14 | 0.04 | 0.00% | 250,000 |
Delayed Quote Toronto S.E., May 21, 2024 at 02:45 pm EDT
More quotes
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patientâs blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patientâs blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
Calendar
2024-05-26
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.71% | 2.56M | |
| +8.63% | 115B | |
| +13.17% | 107B | |
| -12.76% | 22.31B | |
| -3.99% | 21.6B | |
| -7.19% | 18.23B | |
| -39.93% | 17.62B | |
| +6.67% | 14.26B | |
| +33.90% | 12.37B | |
| -28.60% | 8.28B |
- Stock Market
- Equities
- HEM Stock